NICE rejects Perjeta® (pertuzumab) following the Department of Health indecision on funding proposals, calling into question future access when the Cancer Drug Fund ends in January 2014. The Department of Health (DH) could be set to let down thousands of patients with an aggressive form of advanced breast cancer...
More...